image 2 image 4
Skip Navigation Links
 Home 
 Congress Structure 
 Important Dates 
 Venue 
 Registration 
 Pre Registered 
 Hotel Info 
 Abstracts 
 Scientific Program 
 Exhibition 
 Contact Us 
 Personal page 
 Photo and Film Festival 
       XXVI Annual Congress of the Iranian Society of Ophthalmology        بـیــست و ششمین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران
مقاله Abstract


Title: Clinical study of the effect of Sprinolactone as a treatment for Acute Central Serous Chorio-Retinopathy (CSCR) in patients referring to Shahid Sadoughi hospital of Yazd from 2014 to 2015
Author(s): Masoud Reza Manaviat MD,Mohammad Mohsen Keshmirshekan MD, Ali Mohammad Miratashi MD, Hamid Barkhordari MD
Presentation Type: Oral
Subject: Posterior Segment and Uveitis
Others:
Presenting Author:
Name: Mohammad mohsen Keshmirshekan
Affiliation :(optional) Ophthalmic Research Center of Shahid Sadoughi Hospital, Yazd,Iran
E mail: dr.mkeshmirshekan@yahoo.com
Phone:
Mobile: 09131537113
Purpose:

Central Serous Chorio-Retinopathy (CSCR) is an eye disease with unknown cause, demographically believed to be predominantly a disease of men 20 to 45 years of age, in which fluid builds up under the retina and distorts vision. Treatment options are Photodynamic Therapy (PDT) and Laser Photocoagulation which are both invasive and followed by complications, suggesting the need for finding a more appropriate treatment to this disease at its acute phase. In this study, the main objective was to study the effect of Sprinolactone as a treatment for Acute Central Serous Chorio-Retinopathy (CSCR) in patients referring to Shahid Sadoughi hospital of Yazd from 2014 to 2015.

Methods:

In this double blinded randomized clinical trial, total of 40 patients with no prior treatment for CSCR in its acute phase were selected for the study. Subjects with untreated CSCR were subject to physical examination and later Optical Coherence Tomography (OCT) for better confirmation of existence of CSCR. Information was collected through questionnaire, physical examinations and tomography. Subjects were randomly assigned to two groups each consisting of 20 patients, one receiving 25mg Sprinolactone a day for at least one month and the other as placebo. Subjects were instructed to refer to clinic in 15, 30, and 90 days respectively and in each visit besides visual acuity, Center Mocular Thickness (CMT) was also examined in each group using OCT.

Results:

Compared to the placebo group, visual acuity in Sprinolactone group was significantly better, CMT in addition was discerned to be markedly less in comparison with the placebo group. No medicine related complications were reported in this study.

Conclusion:

Based on the results obtained, Sprinolactone was observed to be an appropriately non-invasive treatment in treating acute CSCR cases.

Attachment:





Skip Navigation Links
        صفحه اصلی
        ساختار کنگره
        تاریخ های مهم
        مکان برگزاری
        ثبت نام
        ثبت نام شدگان
        اطلاعات هتل - رزرو
        مقالات
        برنامه کنگره
        جشنواره فیلم و عکس
        نمایشگاه
        تماس با ما
        صفحه شخصی
        جستجوی سخنران
        آرشیو کنگره سالهای گذشته
 
ورود شرکت کنندگان
نام کاربری :
کلمه عبور :
  کلمه عبور خود را فراموش کرده ام.
Total Visits
Find us on Social Media
Congress Count Down
Today Label
Last Month Label
Total Visitors Label